Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan

por Sonoyama, Takuhiro, Kamitani, Akari, Shibata, Risa Y., Seki, Naomi M., Omoto, Shinya, Igarashi, Kenji, Ariyasu, Mari
Publicado 2023

Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings

por Iwata, Satoshi, Sonoyama, Takuhiro, Kamitani, Akari, Shibata, Risa, Homma, Tomoyuki, Omoto, Shinya, Igarashi, Kenji, Ariyasu, Mari
Publicado 2022

Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study

por Shinkai, Masaharu, Sonoyama, Takuhiro, Kamitani, Akari, Shibata, Risa Yokokawa, Seki, Naomi M., Omoto, Shinya, Shinoda, Masahiro, Sato, Takashi, Ishii, Naoki, Igarashi, Kenji, Ariyasu, Mari
Publicado 2022

A Novel Mouse Model of iNKT Cell-deficiency Generated by CRISPR/Cas9 Reveals a Pathogenic Role of iNKT Cells in Metabolic Disease

por Ren, Yue, Sekine-Kondo, Etsuko, Shibata, Risa, Kato-Itoh, Megumi, Umino, Ayumi, Yanagida, Ayaka, Satoh, Masashi, Inoue, Komaki, Yamaguchi, Tomoyuki, Mochida, Keiichi, Nakae, Susumu, Van Kaer, Luc, Iwabuchi, Kazuya, Nakauchi, Hiromitsu, Watarai, Hiroshi
Publicado 2017

Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults

por Sonoyama, Takuhiro, Iwata, Satoshi, Shinkai, Masaharu, Iwata-Yoshikawa, Naoko, Shiwa-Sudo, Nozomi, Hemmi, Takuya, Ainai, Akira, Nagata, Noriyo, Matsunaga, Nobuaki, Tada, Yukio, Homma, Tomoyuki, Omoto, Shinya, Yokokawa Shibata, Risa, Igarashi, Kenji, Suzuki, Tadaki, Hasegawa, Hideki, Ariyasu, Mari
Publicado 2023